PSA 0.2. Would appreciate any comments on the results of my recent PSMA PET CT SCAN:
EXAM: NUC PET PSMA PROSTATE, 07/21/2023 13:33 PM
CLINICAL INDICATIONS: Carcinoma of prostate; ,
COMPARISON: Compared to prior outside PET/CT study dated October 11, 2022
CT DOSE: DLP: 689 mGy x cm
kVp: 120
TECHNIQUE: Approximately 53 minutes following the injection of 5.5 mCi of
Ga-68 PSMA Gozetotide, the patient was positioned on the Siemens Biograph mCT
TOF< PET/CT-64. A low resolution non-contrast CT was obtained from the top of the head through the mid-femurs for use in attenuation correction and anatomic correlation. PET emission scans of this anatomic region were acquired shortly thereafter. Axial, sagittal, coronal and maximal intensity projection reconstruction images were presented for interpretation.
For SUV reference:
SUVmean/max parotid/salivary glands 12.8/17.1
SUVmean/max right hepatic lobe 8.1/12.1
SUVmean/max descending thoracic aorta (level carina) 1.5/2.2
PSMA-expression score*:
High (3): SUV parotid/salivary glands
Intermediate (2): SUV liver
Low (1): SUV blood pool
FINDINGS: Head/Neck: Physiologic activity seen within the lacrimal glands and salivary glands. Normal uptake within the head and neck without gross radiotracer avid abnormality.
Chest: Normal uptake within the chest.
Abdomen/Pelvis: Mild normal physiologic uptake within the liver, bowel, and the spleen. More intense physiologic uptake within the bladder and kidneys. Bilateral inguinal lymph nodes with faint PSMA expression are nonspecific.
Subcentimeter retroperitoneal lymph nodes with faint to low PSMA expression including tiny aortocaval lymph node with focal low PSMA expression SUV max 2.5 (series 4 image 226) and left para-aortic lymph node (series 4 image 215).
Left external iliac with faint to low PSMA expression SUV max 2.8 (series 4 image 278). Status post prostatectomy.
Musculoskeletal: There is physiologic PSMA expression throughout the axial and proximal appendicular skeleton. No focal radiotracer avid lesions are identified.
IMPRESSION:
1. No definite evidence of local recurrence or metastatic prostate cancer.
2. Subcentimeter retroperitoneal and left external iliac lymph nodes with faint to low PSMA expression are indeterminate. Attention on follow-up.
